Novartis bullish on Afinitor cancer drug despite new competition

July 21 (Reuters) - Novartis remains bullish about prospects for its blockbuster cancer drug Afinitor, which achieved sales of $1.58 billion last year, despite competitors lining up to challenge its market position.